PET/CT

Positron emission tomography/computed tomography is a hybrid nuclear medicine imaging technique that helps radiologists spot abnormal metabolic activity. PET/CT is commonly used to diagnose cancers, heart diseases and certain brain disorders, among other conditions.

whole-body pet scanner add-on device presented at #SNMMI 2023

New PET technology offers 'clear improvement' of whole-body scan resolution

The new technology achieves this by way of two add-on detectors that simultaneously scan patients during their whole-body PET exam.

Thumbnail

New prostate cancer PET imaging agent officially available for commercial use

Posluma (flotufolastat F 18) received the U.S. Food and Drug Administration’s approval in May 2023.

folate-based radiopharmaceuticals

Folate-based radiopharmaceuticals could improve detection of gliomas

According to new research, gliomas—a deadly group of brain tumors that are difficult to treat—have increased folate receptor expression, meaning they also show increased uptake of folate-based radiopharmaceuticals on PET imaging.

Thumbnail

Do clinicians want radiologists' management advice? Interviews shed some light on 'unwanted' recommendations

Clinicians only want the information they need to make treatment decisions, rather than advice on what actions they should take, the survey found. 

brain money alzheimer dementia

Will PET imaging be covered alongside new Alzheimer's drugs? CMS dodges topic in new coverage decision

The recent CMS coverage determination did not make any mention of beta-amyloid PET imaging that is necessary for both diagnosing Alzheimer’s and monitoring the effectiveness of related treatments.

Two examples of PSMA-PET scans showing numerous prostate cancer metastases spread throughout the body. Many of these smaller tumors would not have been dected on previous standard-of-care imaging. Photo on left courtesy of SNMMI, right University of Chicago. #PSMAPET

PSMA-PET a more cost-effective option for patients long-term compared to standard prostate imaging

The findings support adopting F-18 DCFPyL PET/CT as the standard of care for prostate cancer staging, authors of a new Scientific Reports paper concluded.

Thumbnail

Radioactive substances unnecessary in new method for measuring brain glucose metabolism

Rather than administering radiolabeled glucose for exams, imagers give patients a small amount of a harmless glucose solution that is said to be equivalent to a can of a carbonated drink.

Thumbnail

Accessibility, reimbursement and other issues limit uptake of PET/CT among oncologists, survey reveals

Difficulty obtaining PET/CT scans was reported by 55% of respondents, with 21% citing this as the greatest barrier in treating classic Hodgkin lymphoma.